Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Seattle Genetics and Agensys Announce Co-Development of Antibody-Drug Conjugate

Published: Monday, July 01, 2013
Last Updated: Monday, July 01, 2013
Bookmark and Share
Seattle Genetics has exercised an option to co-develop an additional ADC under the companies’ existing ADC collaboration agreement.

The ADC, called ASG-15ME, targets the tumor antigen SLITRK6, which is known to be expressed on bladder and lung cancer. Agensys has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 1 trial of ASG-15ME.

“Through our collaboration and co-development agreements with companies like Agensys/Astellas, Seattle Genetics continues to enhance its ability to innovate by combining our industry-leading ADC technology with proprietary cancer targets and antibodies to develop potential new treatments for patients with cancer,” said Eric L. Dobmeier, Chief Operating Officer of Seattle Genetics. “ADCs represent a novel therapeutic approach, and through our pipeline and collaborations more than half of the ADC candidates in clinical development utilize our technology. We look forward to working with Agensys/Astellas to advance ASG-15ME.”

“We’re eager to continue our strong collaboration with Seattle Genetics for ASG-15ME,” said David Stover, Ph.D., Senior Vice President, Agensys Site Head. “This collaboration with Seattle Genetics is in line with our goal to utilize the most advanced technologies to generate more innovative medicines in oncology.”

ASG-15ME is an ADC composed of a fully human antibody directed to SLITRK6, an antigen expressed in multiple solid tumors. Preclinically, ASG-15ME has demonstrated antitumor activity in models of bladder and lung cancer. The antibody is attached to a potent, synthetic cytotoxic agent, monomethyl auristatin E (MMAE), via an enzyme-cleavable linker using Seattle Genetics’ proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into SLITRK6-expressing tumor cells, resulting in targeted cell-killing.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Seattle Genetics and Genmab Collaborate
Collaboration combines Genmab’s proprietary antibodies and Seattle Genetics’ ADC technology. The new ADC program will target AXL expressed on multiple tumor types.
Friday, September 12, 2014
Seattle Genetics and Genmab Enter into New ADC Collaboration
New ADC program will target AXL expressed on multiple tumor types.
Thursday, September 11, 2014
Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer
Seattle Genetics eligible to potentially receive more than $500 million in fees and milestones plus royalties under multi-target deal.
Wednesday, June 26, 2013
Seattle Genetics Reports First Quarter 2013 Financial Results
Total revenues of $57.3 million, including $33.9 million in ADCETRIS® (Brentuximab Vedotin) net product sales.
Thursday, May 09, 2013
Seattle Genetics and Collaborators Highlight Multiple Ab-Drug Conjugate (ADC)
Presentations highlight preclinical data for novel programs and breakthroughs in research to develop highly stable linkers and more potent chemotypes.
Wednesday, April 10, 2013
Seattle Genetics and Oxford BioTherapeutics to Collaborate on ADCs for Cancer
Companies to combine proprietary technologies to generate novel ADC product candidates.
Friday, November 04, 2011
Seattle Genetics Initiates Brentuximab Vedotin Retreatment Clinical Trial
Trial will evaluate tolerability and activity when retreating patients who relapse after previously achieving an objective response to brentuximab vedotin.
Monday, July 27, 2009
Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma
SGN-35 is an ADC that utilizes proprietary technology to empower antibodies by linking them to potent cell-killing drugs.
Friday, June 19, 2009
Seattle Genetics Presents Final Lintuzumab Phase I Clinical Data
Company reports multiple objective responses at well-tolerated doses from a phase I clinical trial of SGN-33 in patients with AML.
Wednesday, June 10, 2009
Seattle Genetics Reports Data from a Weekly Dosing Phase I Clinical Trial of SGN-35 in Lymphoma
Company to present during a Clinical Science Symposium at ASCO Annual Meeting being held in Orlando, Florida.
Tuesday, June 02, 2009
Seattle Genetics Reports Durable Objective Responses with SGN-35 in Lymphoma
Reported demonstrate enhanced activity of dacetuzumab combined with Rituxan in patients with relapsed or refractory Hodgkin lymphoma.
Monday, December 08, 2008
Seattle Genetics Expands SGN-35 Clinical Program with Initiation of Second Phase I Trial
SGN-35 is an antibody-drug conjugate that utilizes company’s technology to empower antibodies by linking them to potent cell-killing drugs.
Monday, March 31, 2008
Seattle Genetics and Agensys Announce Collaboration to Develop ADC Therapies
Both the companies will jointly screen ADC products to an initial target, co-fund all preclinical and clinical development.
Tuesday, January 09, 2007
Seattle Genetics to Present on ADC Technology
The presentations demonstrate the key advances to empower the next generation of targeted cancer therapies.
Tuesday, November 15, 2005
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
A New Way Out for Stem Cells
Researchers at North Carolina State University have discovered that therapeutic stem cells exit the bloodstream in a different manner than was previously thought.
One Giant Leap for the Future of Safe Drug Delivery
Sheffield engineers make major breakthrough in developing silk ‘micro-rockets’ that can be used safely in biological environments.
Designing Potential AIDS Vaccine Candidates
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Anticancer Drug Stops Ebola Virus Molecule in its Tracks
A team of scientists from the University of Oxford have successfully mapped the structure of the Ebola virus molecule that drives the attack strategy and leads to fatal infections in humans.
Assessing the Effectiveness of Genome-Editing Technologies
Researchers have developed a cost-effective and rapid method for assessing edits generated by CRISPR-Cas9 and other genome-editing technologies.
Anthrax Proteins Might Help Treat Cancerous Tumors
Studies in mice reveal novel treatment regimen.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Key to Chronic Fatigue Syndrome is in Your Gut, Not Head
Researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!